Cancer Research

MRI of the brain showing glioblastoma
#Brain cancer #Clinical trial #Drug repurposing #HIV #Oncology #University of Plymouth

Clinical trial to repurpose HIV drugs to treat brain tumours

Drugs developed to treat HIV and AIDS are being trialled for the first time in patients with multiple brain tumours. Scientists at the Brain Tumour Research Centre of Excellence at the University of Plymouth are conducting a clinical trial to see whether using anti-retroviral medications, ritonavir… Read More

#Cancer Research #Editor's Choice #News

CAR-T for large B-cell lymphoma
#Allogene Therapeutics #allogeneic cell therapies #Cell therapy #Lymphoma #Oncology #Phase II trial

Phase II trial investigates allogeneic CAR-T for large B-cell lymphoma

Allogene Therapeutics and Foresight Diagnostics have announced the initiation of a Phase II trial evaluating the use of cemacabtagene ansegedleucel (cema-cel) as part of the first line treatment regimen for newly diagnosed large B-cell lymphoma (LBCL) patients who are likely to relapse. The ALPHA3 trial will… Read More

#Cancer Research #News

#Cancer research #Clinical trials #Funding #iOnctura #Non-small cell lung cancer (NSCLC) #Seed funding

iOnctura announces €80m to progress pipeline  

iOnctura has closed an €80 million Series B financing to continue developing a portfolio of precision oral small molecules that target cancers in novel ways.   The funding round was led by new investor Syncona Limited with participation by the EIC Fund, the venture arm of the European Innovation Council… Read More

#Business & Investment #Cancer Research #News

Cancer cells
#Cancer #Drug discovery #Oncology #Radioligand Therapies (RLTs)

How ready are we for radioligand therapies?  

DDW Editor Reece Armstrong speaks to Jasminka Taleska, Director, RLT HCS Readiness and Policy at Novartis, about the opportunities radioligand therapies (RLTs) represent in treating cancer patients.   RA: What are the potentials of RLTs across cancer?  JT: Cancer is an incredibly complex and heterogeneous disease, and, devastatingly, around 10… Read More

#Cancer Research #Exclusive Content

Vaccine research
#Cancer immunotherapy #Immune response #Immunotherapy #Oncology #University of Turku

Discovery of protein’s role could improve cancer immunotherapies

Researchers at the University of Turku in Finland have discovered that the protein TIMP-1 plays a critical role in the immune system’s defence against cancer. TIMP-1 is produced by dendritic cells, which are responsible for initiating immune responses and boosting the immune system’s ability to recognise… Read More

#Cancer Research #News

Blood cancer
#Antibodies #Blood cancer #CAR-T #Cell therapy #Clinical trials #Events #Haematology

EHA2024: Industry shares latest drug research in blood cancers

A number of key findings in haematological malignancies were revealed at this year’s European Hematology Association (EHA) Congress, which was held in Madrid, Spain 13-16 June. Ibrutinib and talquetamab, Johnson & Johnson Johnson & Johnson shared clinical trial results for its drug candidates Talvey (talquetamab) and… Read More

#Cancer Research #News #Trending News

T cell receptor
#Adaptimmune Therapeutics #Cell therapy #Collaboration #Galapagos #License agreement #Solid tumours

Companies partner on TCR T-cell therapy for head & neck cancer

Adaptimmune Therapeutics and Galapagos have entered into a clinical collaboration agreement to develop Adaptimmune’s TCR T-cell therapy for head and neck cancer and other potential solid tumours. Under the terms of the agreement, Adaptimmune will receive an upfront exclusivity payment of $70 million, plus $15 million… Read More

#Cancer Research #News

microRNA
#Australia #Bowel cancer #Finders University #microRNAs #Oncology

Metformin slows cancer growth using microRNAs, study finds

Australian researchers have analysed how an antidiabetic treatment could help control the growth of tumours, potentially paving the way for the design of better cancer treatments. The new study investigated what happens when metformin, a type 2 diabetes medication, is used to treat colorectal cancer cells,… Read More

#Cancer Research #News

#Biomarkers #Collaboration #Dana-Farber Cancer Institute #OncoHost #Oncology

Companies partner to identify biomarkers for renal cell carcinoma

OncoHost and Dana-Farber Cancer Institute have launched a new study to identify biomarkers for renal cell carcinoma (RCC). Immune-checkpoint inhibitor (ICI) therapy has transformed treatment outcomes for RCC. However, ICIs can also trigger immune-related adverse events and may not benefit all patients. The collaboration… Read More

#Cancer Research #News

Cancer cells
#ASCO #Cancer therapeutics #Cancer treatment #Cancer vaccine #Oncology

Five 2024 breakthroughs in cancer drug research

With the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from 30 May to 3 June, the drug discovery announcements have been coming thick and fast, with many new cancer therapies making significant strides forward in our ability to treat the disease. Lorbrena advances… Read More

#Cancer Research #News #Trending News

Ozempic Insulin injection pen
#ASCO #Case Western Reserve University #Oncology #Weight loss

Ozempic reduces risk of 13 types of cancer

Patients taking semaglutide (the active ingredient in Wegovy and Ozempic) were 19% less likely to develop 13 obesity-related cancers, according to new data presented at ASCO 2024. The research, led by the Case Western Reserve University in Ohio and reported in The Guardian, also found… Read More

#Cancer Research #News #Trending News

Cancer research in lab
#Antigen #Immunology #Oncology #Prostate cancer #University of California San Francisco

Study reveals insights into antigen reactivity in prostate cancer

Researchers from the University of California, San Francisco (UCSF) shared new data on foundational prostate cancer antigen research at the 2024 Annual Meeting of the American Association of Immunologists (AAI) in Chicago. Prostate cancer’s low mutation burden has resulted in very few druggable neoantigens –… Read More

#Cancer Research #News